Medical use of spla2 hydrolysable liposomes

a technology of liposomes and liposomes, which is applied in the direction of drug compositions, peptide/protein ingredients, biocide, etc., can solve the problems of increased efficacy and death of mice, and achieve the effects of prolonging the therapeutic effect reducing the side effects of the therapeutic agent, and reducing neurotoxicity and gastrointestinal toxicity

Inactive Publication Date: 2012-07-12
BIO BEDST
View PDF10 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0031]Other aspects of the present invention relates to methods of reducing the side effects of therapeutic agents, e.g. reducing nephrotoxicity, neurotoxicity and gastro

Problems solved by technology

However, increased efficacy was also often entail

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical use of spla2 hydrolysable liposomes
  • Medical use of spla2 hydrolysable liposomes
  • Medical use of spla2 hydrolysable liposomes

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of sPLA2 Liposomes (LiPlaCis)

[0101]A lipid intermediate is prepared by spray-drying the following a mixture of phospholipids (70 / 25 / 5 mol % DSPC / DSPG / DSPE-PEG2000). The lipids are dissolved in methanol and chloroform. The lipid intermediate is hydrated in an aqueous solution of the anti-cancer drug with agitation. At this step the liposomes are formed but they have a broad size distribution and is a mixture of single-layer and multiple-layer liposomes. In order to get a product with a narrow size distribution and mono-layer liposomes the hydration mixture is extruded by passing it through poly-carbonate filters of appropriate pore sizes. To remove un-encapsulated anti-cancer drug the mixture is purified. A number of techniques are available e.g. dialysis, gel-filfration and ultra-filtration. For preparations ranging from a few liters and above ultra-filtration is the preferred method. Preparations intended for parenteral administration must be sterilized e.g. by sterile-...

example 2

Efficacy in Mice

Methods

[0102]NMRI nude female mice (6-8 weeks) were inoculated subcutaneously into the left flank with 1*107 cells of the human breast carcinoma cell line MT-3. Only mice carrying exponentially growing tumors were selected for the study. Treatment started when tumors had reached a size of 70-80 mm3. Animals received one dose (4 mg / kg cisplatin (Platinol), LiPlaCis or saline) weekly with intra-venous injections into the tail vein starting on day 13 after tumor transplant. Tumor growth was assessed three times a week by measuring two perpendicular diameters and tumor growth was normalized for differing starting sizes by calculating relative tumor volume. Body weight was measured three times a week. Blood samples were taken four days after the first injection to estimate white blood cells and thrombocytes by Coulter counter.

Results:

[0103]LiPlaCis was compared with cisplatin and saline in an efficacy study using MT-3 breast xenografts on nude mice. Cisplatin and LiPlaCis...

example 3

Pharmacokinetics in Rats

Methods:

[0104]Rats (BrlHan:WIST@Mol(GALAS)) were injected with 3 mg / kg cisplatin or LiPlaCis and blood was collected into heparinised tubes (Microvette CB 300 Sarsted). Samples were taken from 10 minutes up to 72 h. A blood volume of 250 μl was taken from each sampling point and immediately placed in an ice-bath and centrifuged (3000×g; 5 min) to obtain the plasma fraction. The plasma-containing tubes were frozen until shipment and subsequent digestion in HCl / HNO3 / H2O2 (60 / 5 / 35 vol %) before platinum analysis using ICP-MS.

Results and Conclusion:

[0105]The experiment revealed that LiPlaCis a long-circulating liposomal form of cisplatin with a T½ of about 20-23 h compared to the 15 minutes for free cisplatin. The area under the curve (AUC) for LiPlaCis was at least 50 times that of cisplatin. See FIG. 2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

The present invention relates to medical use of liposomes, more particular the first medical use of sPLA2 hydrolysable liposomes. Such liposomes may be used for targeted delivery of therapeutic agents to cancerous tissue and in such embodiments; the therapeutic agents are typically small molecule antitumor agents. Other aspects of the inventions relates to methods of reducing the side effects of therapeutic agents, e.g. reducing nephrotoxicity, neurotoxicity and gastrointestinal toxicity of a therapeutic agent. Yet another aspect of the present invention relate to methods of prolonging the therapeutic effect of a therapeutic agent.

Description

FIELD OF THE INVENTION[0001]The present invention relates to liposomal drug delivery systems and their use in therapy.BACKGROUNDLiposomes for Drug Delivery[0002]Liposomes are microscopic spheres which were developed as drug delivery vehicles / systems in the 1980s. The first liposome-based pharmaceuticals were approved for commercial use in the 1990s.[0003]Liposomes have three distinct compartments that can be used to carry various compounds such as drugs: The interior aqueous compartment; the hydrophobic bilayer; and the polar inter-phase of the inner and outer leaflet. Depending on the chemical nature of the compound to be encapsulated it will be localised to either of the compartments.[0004]Liposomes are considered a promising drug delivery system since they passively target tumor tissue by using the pathophysiological characteristics of solid tumors such as hyperplasia and increased vascular permeability but also a defect in lymphatic drainage. These features facilitate extravasat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/127A61K31/282A61K31/555A61K31/704A61K31/337A61P35/00A61K31/203A61K31/192A61K31/519A61K38/14A61K31/475A61K33/24A61K31/505A61K33/243
CPCA61K9/0019A61K9/1271A61K45/06A61K31/282A61K33/24A61K9/1272A61P35/00A61K33/243
Inventor PETERSEN, MORTEN JUSTMELANDER, FREDRIKVIKBJERG, ANDRES FALKPETERSONM, SUNE ALLANMADSEN, MOGNES WINKEL
Owner BIO BEDST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap